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ROLE OF PHARMACOECONOMICS 
IN DEVELOPING COUNTRIES
Most developing countries lack policies that 
encourage the use of economic evaluations in 
medicine selection, be it for public funding, 
prioritization of aid or health insurance. In 
addition, relevant guidelines for reporting 
pharmacoeconomic analyses are not availa-
ble in the majority of countries. Most deve-
loping countries do have National Essential 
Medicine Lists to guide procurement and do-
nation of medicines in the public sector [5]. 
However, the extent to which they employ 
the WHO’s evidence-based approach or other 
guidelines advocating the use of economic 
evaluation criteria in drug selection has not 
been established. Studies conducted by Mori 
et al. [6] and Gavaza et al. [7-9] in a number 
of countries in East, South and West Africa 
have documented a very low availability of 
pharmacoeconomic studies. Some of these 
studies were too poor in quality and narrow 
in scope to be appropriate as evidence to in-
form decision-making. A similar trend has 
also been reported for developing countries 
in Asia [10-12].
Another important observation is that, even 
when pharmacoeconomic studies are availa-
ble, they are not systematically or consistently 
applied in decision-making [6,13]. Experien-
ce shows that many pharmacoeconomic stu-
dies were conducted long after the decisions 
had been made, sometimes simply to justify 
or disqualify those decisions, but more often 
for academic purposes. Cost-effectiveness 
studies of artemisinin-based combination 
therapies for malaria control, for example, 
were conducted in a number of countries af-
ter the decisions to recommend the treatment 
in the respective malaria treatment guide-
lines had already been made [14-16]. Low 
availability and inconsistent application of 
pharmacoeconomic data implies that phar-
macoeconomics so far has had a limited role 
INTRODUCTION
The high price of medicines and increasing 
expenditure on pharmaceuticals is a serious 
concern for governments in low-income 
countries where already over half of the 
population lacks regular access to essential 
medicines [1]. Currently, pharmaceuticals 
in low-income countries consume 30-60 
percent of the recurrent healthcare budgets, 
yet the unmet need for medicines has been 
strongly associated with insufficient public 
spending on pharmaceuticals [2]. Poor fa-
milies mostly rely upon public healthcare 
systems, where shortages of drugs are ram-
pant [3]. In this situation the use of pharma-
coeconomic principles is inevitable when 
an objective is to ensure that the limited re-
sources are efficiently spent on drug thera-
pies with large potentials to improve health. 
While developing countries commonly use 
National Essential Medicine Lists to prio-
ritize the allocation of scarce public fun-
ds between drug therapies, little is known 
about the role of pharmacoeconomics in 
such decisions. In this editorial we there-
fore examine how pharmacoeconomics has 
influenced prioritization decisions between 
drugs in developing countries.
WHAT IS 
PHARMACOECONOMICS?
Pharmacoeconomic analysis involves the 
identification, measurement, valuation and 
comparison of costs and outcomes of alter-
native drug therapies. The underlying aim 
is to maximize treatment outcomes within 
limited budgets [4]. Due to the high alterna-
tive costs of scarce funds, it may be argued 
that pharmacoeconomics is relatively more 
important in developing countries than in 
developed countries. By alternative costs in 
this context we mean the health losses from 
making sub-optimal decisions.
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Editorial
in evidence-based decision-making for drug 
selection in developing countries.
THE WAY FORWARD
Developing countries have limited financial 
resources to address the high burden of com-
municable and non-communicable diseases. 
As a consequence, policy makers and poli-
ticians are looking for politically acceptable 
solutions to bridge the gap between available 
resources and existing healthcare needs. We 
argue that pharmacoeconomics is one such 
solution to increase efficiency in resource al-
location to drug therapies.
Reference pricing and the use of generics has 
been advocated by a number of scholars as 
cost containment mechanisms [10,17]. We 
concur with this focus, but argue that in ad-
dition, it is important to take into account the 
potential of pharmacoeconomic analyses to 
maximize the health benefits of the limited 
resources available. Reference pricing, use 
of generics and pharmacoeconomic analyses 
have complementary roles as cost con-
tainment and efficiency seeking strategies. 
Pharmacoeconomics is also needed for reim-
bursement purposes for the health insurance 
industry, which is growing rapidly in many 
developing countries.
It is possible to increase the application of 
pharmacoeconomics in developing countries, 
despite the existing challenges. In a number 
of countries the seeds of pharmacoeconomics 
have been sown. But much remains to be 
done to facilitate expansion of the field throu-
gh training, advocacy and legislation. For 
example, in 2000 the government of Tanzania 
successfully employed pharmacoeconomic 
analysis to inform the change of policy from 
chloroquine to sulphadoxine-pyrimethami-
ne as first-choice drug for the management 
of uncomplicated malaria [18]. We see no 
substantial reasons why pharmacoeconomic 
principles should not be gradually introduced 
at different levels of the healthcare system. 
There are several steps that can be taken to 
improve the conduct of more pharmacoeco-
nomics studies and increase their utilization 
in decision-making in developing countries:
 - first, more should be done to accelerate 
the introduction of pharmacoeconomics 
and health economics in training curricu-
lums for medical and health science scho-
ols. At the same time, short courses and 
seminars should also be offered to practi-
cing healthcare professionals;
 - second, efforts should be made to impro-
ve the availability of high-quality eviden-
ce to inform decision-making and to en-
sure that such evidence and the processes 
are also transparent;
 - third, given that pharmacoeconomic stu-
dies are relatively expensive and time 
consuming to conduct, policy makers and 
health planners should be ready to invest 
the necessary resources in order to make 
informed policy decisions;
 - fourth, healthcare authorities in develo-
ping countries have not done enough to 
ensure systematic use of economic eva-
luation in drug selection. It is now time to 
put in place legislation and policies that 
encourage the application of pharmaco-
economic principles in drug selection. 
At the same time, we realize that health 
systems may also wish to consider other 
criteria than efficiency when setting he-
althcare priorities. Other arguments, such 
as severity of disease and patients’ ability 
to benefit from the treatment, may be con-
sidered separately.
CONCLUSION
The field of pharmacoeconomics is in its in-
fancy in most developing countries and has 
therefore had little influence on medicine 
selection for treatment guidelines and Natio-
nal Essential Medicine Lists. Despite some 
challenges, we believe it is time to increase 
the use of pharmacoeconomic analyses in 
developing countries through better training, 
advocacy and legislation.
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